Showing 1,528 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Access to healthcare

Merck places children's HIV drug in shared non-profit patent pool

Editor's pick
Reuters
24 February 2015
Hepatitis C treatment

amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

Editor's pick
amfAR
19 February 2015
Pharmaceutical industry

The Drug That Is Bankrupting America

Editor's pick
Huffington Post
18 February 2015
Pharmaceutical industry

Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

Editor's pick
Bio Pharma Dive
16 February 2015
Pharmaceutical industry

How ViiV Healthcare became a pharma favorite for patient groups

Editor's pick
BioPharma Dive
16 February 2015
Pharmaceutical industry

Healthcare: The race to cure rising drug costs

Editor's pick
Financial Times
13 February 2015
New & experimental hepatitis C treatment

FDA revokes breakthrough status for BMS hep C drug

Editor's pick
Fierce Biotech
11 February 2015
Pharmaceutical industry

Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

Editor's pick
The Body Pro
11 February 2015
Men who have sex with men (MSM)

ViiV Launches $10M Initiative to Fight HIV Among Black MSM

Editor's pick
Poz magazine news
6 February 2015
Pharmaceutical industry

GlaxoSmithKline seeks advice on floating HIV division

Editor's pick
The Guardian
5 February 2015
Hepatitis C treatment

What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean

Editor's pick
Wall Street Journal (blog)
5 February 2015
Hepatitis C treatment

Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion

Editor's pick
New York Times
5 February 2015
Hepatitis B

Hepatitis Quest Moves From C to B Under Former Gilead Executives

Editor's pick
Bloomberg
5 February 2015
New & experimental hepatitis C treatment

Merck says hepatitis C drugs to lose breakthrough status

Editor's pick
Reuters
5 February 2015
Access to healthcare

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

Editor's pick
TAG
3 February 2015
Pharmaceutical industry

AbbVie Inc stock drops after expectations for Viekira Pak fall short

Editor's pick
Bidness Etc
2 February 2015
Access to healthcare

Hepatitis C drug access: Europe is the new Africa

Editor's pick
HIV i-Base
30 January 2015
Access to healthcare

Petition: Equitable access to HCV drugs

Editor's pick
Petitionbuzz
30 January 2015
New & experimental HIV treatments

U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Editor's pick
Bristol-Myers Squibb press release
30 January 2015
New & experimental HIV treatments

PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Editor's pick
Janssen press release
30 January 2015
Transmission & prevention

European Advocates Engage with Biomedical Prevention

Editor's pick
AVAC
28 January 2015
Access to healthcare

MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

Editor's pick
Médecins Sans Frontières press release
27 January 2015
New & experimental hepatitis C treatment

Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

Editor's pick
Gilead press release
27 January 2015
Pharmaceutical industry

Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

Editor's pick
Street Insider
26 January 2015